Maze Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	52.23	-100.42	-114.94
Depreciation & Amortization	3.3	4.09	3.82
Loss (Gain) From Sale of Investments	-	-	2.4
Loss (Gain) on Equity Investments	-	-	3.54
Stock-Based Compensation	9.65	8.75	6.74
Other Operating Activities	12.3	7.07	2.48
Change in Accounts Payable	-0.2	0.4	-3.78
Change in Other Net Operating Assets	-1.32	-6.72	0.54
Operating Cash Flow	75.95	-86.83	-99.2
Capital Expenditures	-1.15	-0.44	-1.97
Investment in Securities	-	-	-1.2
Investing Cash Flow	-1.15	-0.44	-3.17
Long-Term Debt Issued	24.48	16.18	-
Net Debt Issued (Repaid)	24.48	16.18	-
Issuance of Common Stock	0.73	0.21	0.15
Other Financing Activities	-3.15	-	-
Financing Cash Flow	92.85	16.39	1.73
Net Cash Flow	167.65	-70.88	-100.65
Free Cash Flow	74.81	-87.27	-101.17
Free Cash Flow Margin	44.66%	-	-
Free Cash Flow Per Share	27.40	-38.14	-50.33
Cash Income Tax Paid	1.23	-	-
Levered Free Cash Flow	52.09	-52.55	-
Unlevered Free Cash Flow	52.09	-52.55	-
Change in Net Working Capital	-4.31	3.35	-

Updated Jan 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q